bioRxiv (Cold Spring Harbor Laboratory)
June 16, 2026
Paulina Clara Dagnino, Irene Acero-Pousa, Gorka Zamora-López et al.
1 citation
preprint
Abstract In recent decades, the psychedelic psilocybin has been studied as a potential treatment for major depressive disorder (MDD), offering an alternative to traditional antidepressants. However, the brain changes underlying the clinical effects of different interventions remain unclear. Here, we investigated the effects of psilocybin and a conventional antidepressant, escitalopram, from the...
Psychedelic Medicine
June 16, 2026
Max Wolff, Samuli Kangaslampi, Richard J. Zeifman et al.
This commentary critically examines the interpretation and analytic choices in Goodwin and colleagues’ recent analysis of therapeutic alliance in psilocybin treatment for treatment-resistant depression. While the authors conclude that alliance did not meaningfully contribute to treatment efficacy, we argue that this interpretation is not supported by the reported results, which are, in...
International Journal of Innovative Technologies in Social Science
June 15, 2026
Olga Szeidl, Joanna Mikołajczyk, Artur Hawajski et al.
Background: Depression is a multifactorial disorder involving neurotransmitter dysregulation, HPA axis hyperactivity, neuroinflammation, and impaired neuroplasticity. While combination psychotherapy and pharmacotherapy remains first-line, ~30% of patients develop TRD. In the last few years ketamine has emerged as a rapid-acting therapeutic option for treatment-resistant cases. Aim: To review...
Research Square
June 15, 2026
Yuping Liu, Bingtao Zhou, Fengxu Qiang et al.
preprint
Abstract Background Mindfulness is reliably associated with lower anxiety and depression, yet the longitudinal within-person dynamics and potential differences between these two forms of emotional distress remain largely unknown. Methods A total of 1,138 participants completed five waves of self-report assessments at two-week intervals. Mindfulness, anxiety, and depression were measured at each...
Acta Psychologica
June 15, 2026
Vera Scheepbouwer, Imke Hanssen, Rhoda Schuling et al.
Objectives: Compassion-based interventions, like Mindfulness-Based Compassionate Living (MBCL), are increasingly recognized as treatments for depression. This study explores the impact of MBCL on self-schemas. Methods: As part of an RCT on MBCL for depression, self-description interviews of approximately 3 min in duration were conducted with 24 patients before and after MBCL and were analyzed...
Ugeskrift for Læger
June 15, 2026
Mikkel Marquardsen
This review presents the status of Mindfulness-Based Cognitive Therapy (MBCT) in the treatment of active depression. The theoretical underpinnings of MBCT are outlined, along with potential mediating and moderating factors influencing treatment outcomes. Several randomised controlled trials indicate that MBCT demonstrates efficacy comparable to other evidence-based interventions. However, MBCT...
Actas Españolas de Psiquiatría
June 15, 2026
Xinrong Zheng, Qijun Zhang, Hesheng Zhuang
This study aimed to investigate the effects of personalized nursing combined with Mindfulness-Based Stress Reduction (MBSR) on anxiety, depression, self-efficacy, quality of life and self-care ability in patients with pneumonia-induced sepsis. This retrospective study enrolled 127 patients with pneumonia-induced sepsis admitted between July 2023 to July 2024. Among them, 59 patients in the...
Journal of Affective Disorders
June 15, 2026
Marc J. Weintraub, Jessica K Jeffrey, Megan Ichinose et al.
Psilocybin-assisted therapy has emerged as a promising treatment for major depressive disorder, but little attention has been paid to the psychotherapy that adjoins psilocybin. Providing an adjunctive psychotherapy that is manualized and evidence-based may make psilocybin treatment more acceptable, effective, and disseminable. We examined the acceptability, feasibility, and clinical outcomes of...
SAIMSARA Journal
June 15, 2026
This scoping review aims to comprehensively map and synthesize the breadth of evidence from original research on the relationship between psilocybin and health, spanning clinical trials, epidemiological surveys, mechanistic experiments, and cross-sectional attitudinal studies. The review uses 145 references and builds its evidence map from 216 original studies with 271241797 total...
Psychiatry International
June 15, 2026
Angel Labra-Lorenzana, Dania Nimbe Lima Sanchez, Christian Alejandro Delaflor-Wagner et al.
Background: This systematic review and meta-analysis evaluates the efficacy and safety of psilocybin-assisted psychotherapy (PAP) for adults with major depressive disorder (MDD). Methods: A PROSPERO-registered search (CRD42024561979) of CENTRAL, Scopus, PsycINFO, and MEDLINE (2010–2024) identified clinical trials assessing PAP. Risk of bias was assessed using RoB 2 for randomized controlled...
Perioperative medicine (London, England)
June 12, 2026
Bowen Zhang, Zhun Wang, Kaili Yu et al.
Pancreaticoduodenectomy (PD) can lead to major trauma in terms of patients' mental health, including severe postoperative depression. This study aimed to investigate the effects of supplementing patient-controlled analgesia with low-dose esketamine on postoperative depression among patients undergoing PD. Eighty patients who were scheduled for PD were randomly assigned to either the control or...
Cognition & Emotion
June 12, 2026
Jenna M Wilson, Jerin Lee, JoNell Strough et al.
Mindfulness has been linked to lower psychological distress. Yet, it remains unclear how, or the mechanism(s) by which, mindfulness reduces psychological distress, particularly during times of heightened, prolonged stress. The present research utilised secondary analysis of data from two independent studies to 1) assess whether greater trait mindfulness protected U.S. adults against...
European Archives of Psychiatry and Clinical Neuroscience
June 12, 2026
Zulkiflu Musa Argungu, Ali Alhaiti, Ebtesam Abdulrahman Jibreel
Major Depressive Disorder (MDD) represents a significant global health challenge, with elevated risks of suicidal ideation. This study evaluated the efficacy of Mindfulness-Based Cognitive Therapy (MBCT) in mitigating depressive symptoms and suicidal ideation among institutionalized patients with MDD in Nigeria. A randomized controlled trial was conducted with 101 participants (MBCT: n = 50,...
Pharmacological Reports
June 12, 2026
Wojciech Ziemichód, Natalia Kajka, Klaudia Kister et al.
The glutamatergic system, particularly N-methyl-D-aspartate (NMDA) receptors, has long been a significant focus of research into new strategies for treating depression, and the clinical success of ketamine, an NMDA receptor antagonist, has been a significant breakthrough. In parallel, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, another key component of the...
Mental Health Weekly
June 12, 2026
Valerie A. Canady
For many patients with major depressive disorder, reaching remission — not just partial response — can significantly alter the course of illness, lowering the risk of relapse and improving day‐to‐day functioning. Yet that goal remains elusive for those with treatment‐resistant depression (TRD), where repeated medication failures, comorbid conditions, and lingering symptoms complicate care. Data...
Psychotherapy and Psychosomatics
June 12, 2026
Thorsten Barnhofer, Maria Niemi, Johannes Michalak et al.
1 citation
INTRODUCTION: Around a third of patients with major depressive disorder experience persistent symptoms despite usual treatments. Identifying scalable, psychological treatment options is critical to reduce the burden associated with difficult-to-treat depression (DTD). We examined the efficacy of mindfulness-based cognitive therapy (MBCT) compared with treatment as usual (TAU) and other active...
Clinics and practice
June 12, 2026
Ana María De Granda-Beltrán, Alejandro Porras-Segovia, Daniel Núñez-arias et al.
Background: Treatment-resistant depression (TRD) poses a major clinical challenge, particularly when accompanied by suicidal behavior. Intranasal esketamine has demonstrated rapid antidepressant effects in TRD, but real-world comparative evidence remains limited. Methods: We conducted a six-month naturalistic prospective cohort study in two Spanish mental health centers, including 62 TRD...
Journal of Psychiatric Research
June 12, 2026
Juliana Lima Constantino, Tobias Stephan Freimann, Jens H van Dalfsen et al.
Oral esketamine is a potentially effective and well-tolerated treatment for treatment-resistant depression (TRD). However, around 50% of TRD individuals treated with oral esketamine do not achieve response, and this variation in response may be accounted for by interindividual differences between patients. Efforts to develop effective and personalized depression treatment strategies are...
Journal of Surgery and Medicine
June 11, 2026
Davon Lee, Elizabeth Beyene, Da’Jhai Monroe et al.
Background/Aim: Ketamine is frequently administered for analgesia and sedation during burn dressing changes, but its potential psychological impact remains a concern. This study assessed whether ketamine exposure during early burn care is associated with subsequent depression, acute stress reaction (ASR), or post-traumatic stress disorder (PTSD) in patients with major burns. Methods: A...
Australasian Psychiatry
June 11, 2026
Eden Mane, Saras Mane
ObjectivesTo systematically review the effectiveness, safety, and care models of telehealth-supported ketamine for depression and/or anxiety in adults and consider implications for Australasian clinical practice.MethodsFollowing PRISMA 2020, we searched for randomised or observational studies of adults receiving at-home telehealth-supported ketamine for depression and/or anxiety, to August...